Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

331 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
Fisher RI, Rosenberg SA, Fyfe G. Fisher RI, et al. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S55-7. Cancer J Sci Am. 2000. PMID: 10685660 Clinical Trial.
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma.
Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Margolin KA, Rayner AA, Sznol M, Parkinson DR, Paietta E, et al. Hawkins MJ, et al. Among authors: fisher ri. J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):74-8. doi: 10.1097/00002371-199401000-00010. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8110733 Clinical Trial.
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.
Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, et al. Sparano JA, et al. Among authors: fisher ri. J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):216-23. doi: 10.1097/00002371-199410000-00006. J Immunother Emphasis Tumor Immunol. 1994. PMID: 7834121 Clinical Trial.
A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients.
Sosman JA, Kefer C, Fisher RI, Jacobs CD, Pumfery P, Ellis TM. Sosman JA, et al. Among authors: fisher ri. J Immunother Emphasis Tumor Immunol. 1995 Apr;17(3):171-80. doi: 10.1097/00002371-199504000-00006. J Immunother Emphasis Tumor Immunol. 1995. PMID: 7613643 Clinical Trial.
In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
McMannis JD, Fisher RI, Creekmore SP, Braun DP, Harris JE, Ellis TM. McMannis JD, et al. Among authors: fisher ri. J Immunol. 1988 Feb 15;140(4):1335-40. J Immunol. 1988. PMID: 3257776
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, Sparano J, Fisher RI, Weiss G, et al. Dutcher JP, et al. Among authors: fisher ri. J Clin Oncol. 1991 Apr;9(4):641-8. doi: 10.1200/JCO.1991.9.4.641. J Clin Oncol. 1991. PMID: 2066760 Clinical Trial.
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
Parkinson DR, Fisher RI, Rayner AA, Paietta E, Margolin KA, Weiss GR, Mier JW, Sznol M, Gaynor ER, Bar MH, et al. Parkinson DR, et al. Among authors: fisher ri. J Clin Oncol. 1990 Oct;8(10):1630-6. doi: 10.1200/JCO.1990.8.10.1630. J Clin Oncol. 1990. PMID: 2213100 Clinical Trial.
High-dose aldesleukin in renal cell carcinoma: long-term survival update.
Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. Fisher RI, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S70-2. Cancer J Sci Am. 1997. PMID: 9457398 Clinical Trial.
Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells.
Futscher BW, Micetich KC, Barnes DM, Fisher RI, Erickson LC. Futscher BW, et al. Among authors: fisher ri. Cancer Commun. 1989;1(1):65-73. doi: 10.3727/095535489820875444. Cancer Commun. 1989. PMID: 2534817
CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells.
Ellis TM, Simms PE, Slivnick DJ, J├Ąck HM, Fisher RI. Ellis TM, et al. Among authors: fisher ri. J Immunol. 1993 Sep 1;151(5):2380-9. J Immunol. 1993. PMID: 8103064
331 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback